Abstract:Abstract Objective The present study was aimed to determine the differentially expressed proteins (DEPs) between paired samples of cervical cancer (CC) and paracancerous tissue by quantitative proteomics and to examine the effects of DUSP7 expression on tumorigenesis and progression of CC. Materials and methods Proteomic profiles of three paired samples of CC and paracancerous tissue were quantitatively analyzed to identify the DEPs. The gene functions of the DEPs were presented based on bioinformatics analysis in combining with bibliographical information. The expression of the DEPs was validated by IHC examination in the CC tissue arrays. The relationship between the DEPs expression and patients’ clinicopathological characteristics and prognosis were evaluated using the Spearman rank correlation test and Kaplan-Meier survival analysis respectively. The effects of the selected DEPs on CC progression were examined in SIHA (human CC cell line) cells. Results According to the TMT (Tandem Mass Tags) ratios (≥ 1.5 or ≤ 0.5 ), a total of 129 proteins were found to be differentially expressed in all 3 pairs of samples with a p value < 0.05. To investigate gene functions of these DEPs in tumor growth and progresssion, Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis was performed. Three DEPs, HRAS, DUSP7, and PLD1, and P-ERK1/2, associated with RAS pathway, were selected for further investigation. Western Blot and IHC staining analyses confirmed the results from quantitative proteomic analysis showing that HRAS, P-ERK1/2, and PLD1 levels were increased whereas DUSP7 level was decreased in CC tissue compared with the paired normal paracancerous tissues. The IHC results from the CC TMA analysis showed that the decreased expression of DUSP7 (P = 0.045 and 0.044, respectively) and increased expression of PLD1 (P = 0.046 and 0.028, respectively) were significantly associated with a tumor size > 2 cm and parametrial infiltration. In addition, the decreased expression of DUSP7 and increased expression of PLD1 and p-ERK1/2 were adversely related to patients’ relapse (P = 0.003, 0.040, and 0.001, respectively) and survival (P = 0.034, 0.001, and 0.006, respectively). The expression of HRAS and p-ERK1/2 was decreased in DUSP7-SIHA cells compared to NC-SIHA cells (P = 0.0003 and 0.0026, respectively). Biological functions in vitro, including invasion, migration, and proliferation, and tumor formation in vivo were decreased in the DUSP7-SIHA cells (all P < 0.05), yet increased in the siDUSP7-SIHA cells (all P < 0.05). Conclusions DUSP7 is decreased in cervical cancer tissues compared to normal tissues. Increasing or decreasing DUSP7 expression was found to significantly reduce or enhance the anchorage-independent growth of SIHA cells, respectively. The biological function of DUSP7 is possibly achieved through dephosphorylation of the ERK1/2 and inactivation of the RAS pathway. Up-regulating the expression of DUSP7 may be potential useful for the prevention or treatment of CC.

Dusp6 Inhibits Epithelial-Mesenchymal Transition in Endometrial Adenocarcinoma Via ERK Signaling Pathway.

Dual-specificity Phosphatase 6 (dusp6), a Negative Regulator of FGF2/ERK1/2 Signaling, Enhances 17Β-Estrodial-induced Cell Growth in Endometrial Adenocarcinoma Cell

A mechanism study of DUSP1 in inhibiting malignant progression of endometrial carcinoma by regulating ERK/AP-1 axis and dephosphorylation of EPHA2

DUSP1 inhibits cell proliferation, metastasis and invasion and angiogenesis in gallbladder cancer.

DUSP6 is upregulated in metastasis and influences migration and metabolism in pancreatic cancer cells

Dual-Specificity Phosphatase 1 Deficiency Induces Endometrioid Adenocarcinoma Progression Via Activation of Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase Pathway

Overexpression of DUSP6 Enhances Chemotherapy-Resistance of Ovarian Epithelial Cancer by Regulating the ERK Signaling Pathway.

Functional Role of DUSP6 in the EGFR-mediated Progression of Head and Neck Squamous Cell Carcinoma

DUSP7 inhibits cervical cancer progression by inactivating the RAS pathway

Abstract B002: ARID1A loss activates MAPK signaling via DUSP4 downregulation: a mechanistic insight in endometrial carcinoma

Pharmacological Inhibition of DUSP6 Suppresses Gastric Cancer Growth and Metastasis and Overcomes Cisplatin Resistance.

Silencing of Dusp6 Gene by Rnai-Mediation Inhibits Proliferation and Growth in Mda-Mb-231 Breast Cancer Cells: an in Vitro Study

MiR-361-3p Regulates ERK1/2-induced EMT Via DUSP2 Mrna Degradation in Pancreatic Ductal Adenocarcinoma.

A Study on the Relation of the Mitogen-Activated Protein Kinase Signaling Pathway to the Clinicopathological Features of the DUSP6 Expression in Hepatocellular Carcinoma

Loss Of Expressions Of Dusp6, Sprouty4, And Sef, Negative Regulators Of Fgf2/Erk1/2 Signaling, In The Endometrium Of Women With Adenomyosis

Dual-specificity Phosphatase 6 Predicts the Sensitivity of Progestin Therapy for Atypical Endometrial Hyperplasia.

DUS4L suppresses invasion and metastasis in LUAD via modulation of PI3K/AKT and ERK/MAPK signaling through GRB2

FUT6 Suppresses the Proliferation, Migration, Invasion, and Epithelial-Mesenchymal Transition of Esophageal Carcinoma Cells via the Epidermal Growth Factor Receptor/Extracellular Signal-Regulated Kinase Signaling Pathway

DUSP5 regulated by YTHDF1-mediated m6A modification promotes epithelial-mesenchymal transition and EGFR-TKI resistance via the TGF-β/Smad signaling pathway in lung adenocarcinoma

Higher Intratumor Than Peritumor Expression of DUSP6/MKP-3 is Associated with Recurrence after Curative Resection of Hepatocellular Carcinoma.

TORC2/3-mediated DUSP1 Upregulation is Essential for Human Decidualization.